Literature DB >> 6271820

Clinical relevance of cannabis tolerance and dependence.

R T Jones, N L Benowitz, R I Herning.   

Abstract

Psychoactive drugs are often widely used before tolerance and dependence is fully appreciated. Tolerance to cannabis-induced cardiovascular and autonomic changes, decreased intraocular pressure, sleep and sleep EEG, mood and behavioral changes is acquired and, to a great degree, lost rapidly with optimal conditions. Mechanisms appear more functional than metabolic. Acquisition rate depends on dose and dose schedule. Dependence, manifested by withdrawal symptoms after as little as 7 days of THC administration, is characterized by irritability, restlessness, insomnia, anorexia, nausea, sweating, salivation, increased body temperature, altered sleep and waking EEG, tremor, and weight loss. Mild and transient in the 120 subjects studied, the syndrome was similar to sedative drug withdrawal. Tolerance to drug side effects can be useful. Tolerance to therapeutic effects or target symptoms poses problems. Clinical significance of dependence is difficult to assess since drug-seeking behavior has many determinants. Cannabis-induced super sensitivity should be considered wherever chronic drug administration is anticipated in conditions like epilepsy, glaucoma or chronic pain. Cannabis pharmacology suggests ways of minimizing tolerance and dependence problems.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6271820     DOI: 10.1002/j.1552-4604.1981.tb02589.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  52 in total

1.  Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner.

Authors:  S Tai; W S Hyatt; C Gu; L N Franks; T Vasiljevik; L K Brents; P L Prather; W E Fantegrossi
Journal:  Pharmacol Res       Date:  2015-09-08       Impact factor: 7.658

Review 2.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

Review 3.  The marijuana withdrawal syndrome: diagnosis and treatment.

Authors:  Margaret Haney
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

4.  Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol.

Authors:  Diana L McKinney; Michael P Cassidy; Lauren M Collier; Billy R Martin; Jenny L Wiley; Dana E Selley; Laura J Sim-Selley
Journal:  J Pharmacol Exp Ther       Date:  2007-10-29       Impact factor: 4.030

Review 5.  Review. Evidence-based treatments of addiction.

Authors:  Charles P O'Brien
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-10-12       Impact factor: 6.237

Review 6.  Marijuana dependence: not just smoke and mirrors.

Authors:  Divya Ramesh; Joel E Schlosburg; Jason M Wiebelhaus; Aron H Lichtman
Journal:  ILAR J       Date:  2011

7.  Long-lasting increase of alcohol relapse by the cannabinoid receptor agonist WIN 55,212-2 during alcohol deprivation.

Authors:  José Antonio López-Moreno; Gustavo González-Cuevas; Fernando Rodríguez de Fonseca; Miguel Navarro
Journal:  J Neurosci       Date:  2004-09-22       Impact factor: 6.167

8.  The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats.

Authors:  Marco Bortolato; Gian Nicola Aru; Roberto Frau; Marco Orrù; Grant Christopher Luckey; Gianluca Boi; Gian Luigi Gessa
Journal:  Psychopharmacology (Berl)       Date:  2004-07-28       Impact factor: 4.530

Review 9.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

10.  Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.

Authors:  Eugene W Schwilke; David M Schwope; Erin L Karschner; Ross H Lowe; William D Darwin; Deanna L Kelly; Robert S Goodwin; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-10-15       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.